Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) presented clinical imaging data at the 2026 SIR meeting showing the TAMP therapy platform enables localized intra-arterial delivery of gemcitabine for locally advanced pancreatic cancer (LAPC).
Post-treatment FDG PET/CT showed dramatic reductions in tumor metabolic activity after eight cycles over two months, suggesting potential treatment response with reduced systemic toxicity and earlier detection of effect versus anatomy.
Positive
- PET/CT showed dramatic reductions in FDG avidity after treatment
- Eight cycles of intra-arterial chemotherapy administered over two months
- TAMP delivery via RenovoCath may reduce systemic toxicity
Negative
- Results presented as an abstract at a scientific meeting, not a randomized Phase III readout
- Findings are preliminary and described as a promising approach rather than definitive proof
News Market Reaction – RNXT
On the day this news was published, RNXT gained 0.98%, reflecting a mild positive market reaction. This price movement added approximately $450K to the company's valuation, bringing the market cap to $46.40M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RNXT gained 3.52% while momentum peers were mixed (e.g., BRNS up 8.67%, VRCA down 6.41%). Broader biotech peers (PSTV, RENB, TELO, TPST) show varied moves, indicating stock-specific rather than sector-driven dynamics.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Phase III enrollment update | Positive | +5.5% | TIGeR‑PaC trial surpassed 100 randomized patients, nearing enrollment completion. |
| Feb 26 | Abstract acceptance SIR | Positive | -5.0% | Acceptance of TAMP PET/CT response abstract for presentation at SIR 2026. |
| Feb 04 | Clinical data SIO | Positive | -4.5% | SIO data showing reliable intra‑arterial pressure measurement with TAMP platform. |
| Jan 28 | Abstract acceptance SIO | Positive | +0.2% | SIO 2026 abstract on real‑time pressure measurements to optimize chemotherapy delivery. |
| Jan 08 | ASCO GI PK/PD data | Positive | +13.9% | ASCO GI data showing favorable PK/PD profile for intra‑arterial gemcitabine versus IV. |
Clinical trial and TAMP data updates have produced mixed but generally modest reactions, with 3 aligned positive moves and 2 negative divergences around similar news and an average move of 2.01%.
Over recent months, RenovoRx has repeatedly highlighted its TAMP™ platform through clinical data and conference presentations, including ASCO GI, SIO, and SIR meetings, as well as progress in the Phase III TIGeR‑PaC trial with enrollment surpassing 100 randomized patients. Same‑tag clinical updates have sometimes led to strong gains (e.g., a 13.86% move on January 8, 2026) but also occasional selloffs after abstract acceptances. Today’s SIR outcome data further extends this clinical narrative, reinforcing earlier PK/PD and procedural optimization findings.
Historical Comparison
Past clinical‑trial news for RNXT averaged a 2.01% move with mixed reactions to data and abstract updates. Today’s SIR outcome data fits this pattern of modest but meaningful responses to TAMP platform progress.
Clinical‑trial news has progressed from early TAMP PK/PD results and procedural optimization to major Phase III TIGeR‑PaC enrollment milestones and now PET/CT metabolic response data in locally advanced pancreatic cancer.
Regulatory & Risk Context
RenovoRx has an effective Form S-3 shelf filed on 2025-11-14 to offer up to $50,000,000 of mixed securities, providing flexibility to raise capital over time for TIGeR‑PaC development and RenovoCath commercialization. One 424B5 takedown has been recorded, but remaining capacity and usage details are not specified.
Market Pulse Summary
This announcement highlights PET/CT metabolic imaging data supporting RenovoRx’s TAMP™ platform for localized gemcitabine delivery in locally advanced pancreatic cancer, with eight intra‑arterial cycles over 2 months and notable reductions in FDG avidity. It builds on prior ASCO GI and SIO findings and complements the ongoing Phase III TIGeR‑PaC trial. Investors may watch for future TIGeR‑PaC readouts, further conference data, and how the company utilizes its $50,000,000 Form S‑3 capacity to fund development and commercialization.
Key Terms
tamp medical
trans-arterial micro-perfusion medical
pet/ct medical
fdg medical
fluorodeoxyglucose medical
locally advanced pancreatic cancer medical
intra-arterial medical
systemic toxicity medical
AI-generated analysis. Not financial advice.
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer
Metabolic Imaging, Used to Evaluate Therapeutic Outcome Following Treatment with TAMP, Shows a Notable Reduction in Tumor Activity Suggesting a Potential Treatment Response
MOUNTAIN VIEW, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract submitted by experts from Moffitt Cancer Center was presented at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto, Canada.
The abstract, entitled “What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer,” was presented on April 13, 2026 by a multidisciplinary team of experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx’s Medical Advisory Board.
The abstract examined the effectiveness of local, targeted intra-arterial chemotherapy administration using RenovoRx’s patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform. By delivering chemotherapy directly near the tumor site, TAMP helps to overcome the poor vascularity typical of solid tumors like locally advanced pancreatic cancer (LAPC), where intravenous chemotherapy is often less effective. Additionally, the abstract assessed the potential application of metabolic imaging, FDG (fluorodeoxyglucose) PET/CT, in evaluating therapeutic outcomes following targeted intra-arterial drug-delivery via TAMP in patients with refractory disease.
The study concluded that TAMP is a promising approach for localized delivery of chemotherapeutic agents for the treatment of solid tumors such as LAPC, offering the potential for enhanced therapeutic drug-delivery with reduced systemic toxicity. Metabolic imaging further demonstrated dramatic reductions in FDG avidity, suggesting treatment response even when tumor size changed minimally. Eight cycles of intra-arterial chemotherapy were administered over 2 months, using the TAMP therapy platform, which is enabled by the Company’s RenovoCath device. Post-treatment imaging results indicated that PET/CT may detect early treatment response before anatomical changes occur.
“Patients diagnosed with LAPC face a challenging prognosis, due in part to a dense, hypovascular stroma that can restrict the effectiveness of traditional systemic (namely intravenous) chemotherapy,” said Dr. Al-Roubaie. “Systemic chemotherapeutic administration is often associated with considerable toxicity and suboptimal tumor penetration. The TAMP therapy platform aims to increase local drug concentration directly near the tumor site while reducing systemic exposure.”
Dr. Al-Roubaie continued, “These findings support RenovoRx’s TAMP therapy platform and its ability for local intra-arterial chemotherapeutic delivery directly near the tumor site and the potential for reduced toxicity for patients. These findings may complement RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial evaluating the company’s lead drug-device product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of LAPC.”
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In its first full year of commercial efforts, RenovoRx generated approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the results and public presentation of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Investor Relations Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com
Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com
